Research programme: endothelial dysfunction therapeutics - Antibe Therapeutics
Alternative Names: ATB-901Latest Information Update: 08 Jul 2011
Price :
$50 *
At a glance
- Originator Antibe Therapeutics
- Class
- Mechanism of Action Antioxidants; Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Erectile dysfunction; Vascular disorders
Most Recent Events
- 08 Jul 2011 Discontinued - Preclinical for Erectile dysfunction in United Kingdom (unspecified route)
- 08 Jul 2011 Discontinued - Preclinical for Vascular disorders in Canada (unspecified route)
- 01 Feb 2007 No development reported - Preclinical for Erectile dysfunction in United Kingdom (unspecified route)